remote ischaemic conditioning in stemi patients in africa

Conditions: STEMI; Remote Ischaemic Conditioning; Myocardial Reperfusion Injury

Summary: the ric-africa trial is a multi-centre, sham-controlled, randomised controlled trial (rct) involving 1400 st-segment elevation myocardial infarction (stemi) patients presenting within ≤ 24 hours of myocardial infarction (mi) onset, across approximately 25 sites in 7 african countries (south africa, kenya, sudan, uganda, mozambique, senegal and mauritius). patients presenting with stemi and deemed ineligible for the ric africa rct because they present \>24 hours from mi onset but less than 72 hours, will be recruited into the observational arm of the study with the same endpoints as the trial. the purpose of the rct is to determine whether remote ischaemic conditioning (ric) can reduce the rates of all-cause death and early post-myocardial heart failure at 30-days in stemi patients treated predominantly with thrombolytic therapy.

background: remote ischaemic conditioning (ric) using transient limb ischaemia and reperfusion has been shown to reduce myocardial infarct size in animal studies and small proof-of-concept clinical studies in st-segment elevation myocardial infarction (stemi) patients. however, ric failed to improve clinical outcomes in the large european condi-2/eric-ppci multi-centre randomised clinical trial. potential reasons for this failure include the low-risk patients recruited into the study and the fact that patients received timely and optimal reperfusion therapy by primary percutaneous coronary intervention. the ric-africa trial will investigate whether ric can improve clinical outcomes in higher-risk stemi patients treated by thrombolysis in africa. study design: the ric-africa trial is a multi-centre, sham-controlled, randomised controlled trial (rct) involving 1400 st-segment elevation myocardial infarction (stemi) patients presenting within ≤ 24 hours of myocardial infarction (mi) onset, across approximately 20 sites in 7 african countries (south africa, kenya, sudan, uganda, mozambique, senegal and mauritius). patients will be randomised to receive either ric or sham control initiated prior to thrombolysis and applied daily for the next 2 days. the ric protocol will comprise four 5-minute cycles of inflation (to 20mmhg above systolic blood pressure) and deflation of an automated pneumatic cuff placed on the upper arm. the sham control protocol will comprise four 5-minute cycles of low-pressure inflation (to 20mmhg) and deflation by a visually identical pneumatic cuff. the primary composite endpoint will be all-cause death and new-onset heart failure at 30-days post stemi. patients presenting with stemi and deemed ineligible for the ric africa rct because they present \>24 hours from mi onset but less than 72 hours, will be recruited into the observational arm of the study with the same endpoints as the trial. implications: the ric-africa trial will determine whether ric can reduce rates of death and prevent heart failure in higher-risk stemi patients treated by thrombolytic therapy in africa, thereby potentially providing a low-cost, non-invasive therapy for improving health outcomes.

Eligibility criteria:
we will be recruiting 3 different strata of stemi patients. 1. adult patients (≥18 years old) presenting with stemi receiving thrombolytic therapy within guideline-recommended time (i.e., within \<12 hours of most severe chest pain onset). 2. adult patients (≥18 years old) presenting with stemi who are ineligible for thrombolysis because they present outside of guideline-recommended time (\<12 hours) but within 24 hours of most severe chest pain onset. 3. adult patients (≥18 years old) presenting with evidence of stemi who do not receive thrombolysis and who present ≥24 hours and within 72 hours of most severe chest pain onset. interventional arm of the study: randomized control trial patients who are deemed eligible for randomization into the trial on account of presentation with stemi within 24 hours, will be eligible for the interventional arm of the study if the following inclusion/exclusion criteria are met. inclusion criteria i. adult patients (≥18 years old) presenting with suspected stemi (st-elevation at the j-point in two contiguous leads ( ≥ 0.2mv in men or ≥ 0.15mv in women in leads v2-v3 and/or ≥ 0.1mv in other lead); and ii. within 24 hours of onset of myocardial infarction as deemed by the attending clinician; and iii. signed informed consent. exclusion criteria i. stemi patients due to undergo primary percutaneous coronary intervention; ii. stemi patients presenting with cardiogenic shock or haemodynamic instability as defined by: systolic blood pressure (sbp) measurement of \ 2.0 mmol/l; iii. contraindications for the use of ric or sham-control on either arm such as: 1. severe active skin disease/burns on both arms; or 2. bilateral upper limb amputations; or 3. evidence of acute limb ischaemia on either arm; or 4. active upper limb gangrene of any digits; 5. breast cancer with lymph-node involvement on the ipsilateral side of ric; or 6. bilateral arteriovenous fistulae needed for haemodialysis. iv. inter-current disease with an expected life expectancy of less than 24 hours; v. contra-indication to thrombolytic therapy in patients presenting within guideline-recommended time (\<12 hours). observational arm of the study patients who are deemed ineligible for randomization into the trial on account of presentation beyond 24 hours, will be eligible for the observational arm of the study if the following inclusion/exclusion criteria are met. inclusion criteria i. signed informed consent; and ii. clinical evidence of stemi older than 24 hours and less than 72 hours as defined by: 1. compatible history with maximal chest pain between 24 -72 hours prior to presentation; and 2. compatible biomarkers (elevated cardiac troponin); and 3. ecg compatible with recent stemi; and/or 4. compatible echocardiography. exclusion criteria i. refusal or inability to sign informed consent.

Keywords: cardioprotection ischaemia/reperfusion injury st-elevation myocardial infarction hospitalisation for post-myocardial infarction heart failure remote ischaemic conditioning cardiovascular mortality stemi